Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprising instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent probe binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers reagent kits, which include sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington. Show more
Location: 2701 Eastlake Avenue East, Seattle, WA, 98102, United States | Website: https://www.nautilus.bio | Industry: Biotechnology | Sector: Healthcare
Market Cap
90.98M
52 Wk Range
$0.66 - $3.09
Previous Close
$0.72
Open
$0.71
Volume
129,406
Day Range
$0.71 - $0.73
Enterprise Value
-28.71M
Cash
147.9M
Avg Qtr Burn
-13.68M
Insider Ownership
33.34%
Institutional Own.
48.64%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|